LAG-3 Inhibitors for the Treatment of Lung Cancer

The immune checkpoint LAG-3 (lymphocyte activation gene 3) or CD223/FDC protein is located on chromosome 12 of the human genome. Enhancement of antitumor response is by modulation of signaling pathways between T lymphocytes and antigen-presenting cells and reestablishment of cytotoxic T lymphocyte activity. In recent years, LAG-3 has been taken into consideration as a prognostic tumor marker for therapy of cancer because it has turned into a potential target for immunotherapy. This book chapter aims to analyze the molecular constitution and connections of LAG 3 including its expression, signaling pathways involved in its clinical trial results have shown that LAG-3 blocking Monoclonal Antibody, Relatlimab, Nivolumab, and Ipilimumab are both effective and safe. Investigation of the functional characteristics of LAG-3 may allow the development of better, non-invasive therapies for lung cancer.